Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: Study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Buhmann, Raymund ^a,b   Michael, Stanglmaier ^e   Juergen, Hess ^e   Horst, Lindhofer ^d,e   Peschel, Christian ^c   Kolb, Hans Jochem ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TRION Research GmbH   (Germany)

^e TRION Pharma GmbH   (Germany)

Author keywords

Allogeneic Transplantation; B Cell Malignancies; Donor Lymphocyte Infusion; Immunotherapy; Trifunctional Bispecific Antibody (trAb)

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; CD3 ANTIBODY; FBTA 05; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTICLE; B CELL LYMPHOMA; BONE PAIN; BRONCHOSPASM; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CELLULAR IMMUNITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; IMMUNOREGULATION; INCIDENCE; INDUCTION CHEMOTHERAPY; LARGE CELL LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD3; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; LYMPHOMA; LYMPHOMA, B-CELL; RESEARCH DESIGN; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84879832972     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-160     Document Type: Article

References (29)

1. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004, 10:579-590. 10.1016/j.bbmt.2004.05.008, 15319770.
2. Butcher BW, Collins RH. The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant 2005, 36:1-17. 10.1038/sj.bmt.1705008, 15895112.
3. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147:614-633. 10.1111/j.1365-2141.2009.07886.x, 19735262.
4. Bierman PJ, Sweetenham JW, Loberiza FR, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003, 21:3744-3753. 10.1200/JCO.2003.08.054, 12963703.
5. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407-4412. 10.1200/JCO.2003.05.501, 14645431.
6. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004, 22:2419-2423. 10.1200/JCO.2004.09.092, 15197204.
7. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536. 10.1182/blood-2008-01-136242, 18411419.
8. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
9. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
10. Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000, 109:81-88. 10.1046/j.1365-2141.2000.01965.x, 10848785.
11. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368. 10.1038/sj.onc.1206939, 14576843.
12. Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schroder P, Lindhofer H. Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 2008, 123:1181-1189. 10.1002/ijc.23626, 18546289.
13. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001, 98:2526-2534. 10.1182/blood.V98.8.2526, 11588051.
14. Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res 2012, 72:3958-3966. 10.1158/0008-5472.CAN-12-0146, 22745368.
15. Ruf P, Schafer B, Eissler N, Mocikat R, Hess J, Ploscher M, Wosch S, Suckstorff I, Zehetmeier C, Lindhofer H. Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model. Journal of translational medicine 2012, 10:219. 10.1186/1479-5876-10-219, 3543252, 23134699.
16. Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D, Lindhofer H, Kolb HJ. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2009, 43:383-397. 10.1038/bmt.2008.323, 18850012.
17. Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert opinion on investigational drugs 2008, 17:1553-1558. 10.1517/13543784.17.10.1553, 18808314.
18. Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert review of hematology 2010, 3:429-441. 10.1586/ehm.10.32, 3426446, 21083034.
19. Slavin S, Morecki S, Weiss L, Or R. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Crit Rev Oncol Hematol 2003, 46:139-163. 10.1016/S1040-8428(02)00108-7, 12711359.
20. ICH E6 Harmonised Guideline for Good Clinical Practice 1996, Geneva, Switzerland: ICH, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH E6.
21. Declaration of Helsinki - Ethical principles for medical research involving human subjects 2008, Seoul, Korea: World Medical Association, Proceedings of the 59th WMA General Assembly.
22. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel?. MAbs 2009, 1:539-547. 10.4161/mabs.1.6.10015, 2791310,2791310, 20073127.
23. Hess J, Ruf P, Lindhofer H. Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncol 2012, 8:73-85. 10.2217/fon.11.138, 22149036.
24. Muller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010, 24:89-98. 10.2165/11530960-000000000-00000, 20199124.
25. Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:437-441. 10.1038/sj.bmt.1705074, 15980879.
26. Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R, Linch DC, Goldstone AH, Peggs KS, Mackinnon S. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:50-58.
27. Riechelmann H, Wiesneth M, Schauwecker P, Reinhardt P, Gronau S, Schmitt A, Schroen C, Atz J, Schmitt M. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 2007, 56:1397-1406. 10.1007/s00262-007-0283-6, 17273869.
28. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 2006, 107:1564-1569. 10.1182/blood-2005-07-2738, 16234351.
29. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 2008, 36:997-1003. 10.1016/j.exphem.2008.03.005, 18495330.